Physician profile
Atul Kumar
NPI 1649287095
$8,747.21
in general payments reported to CMS, 2019-2025
17 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,729 · 2021: $4,564 · 2022: $213 · 2023: $2,100 · 2024: $17.02 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,100 · Food and Beverage: $124 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,100.00 |
| Food and Beverage | $124.24 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $5,013.75 | 2021-2023 | Libtayo |
| Beigene, LTD. | $1,650.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $1,110.00 | 2020 | |
| Blueprint Medicines Corporation | $618.75 | 2020 | |
| Novocure Gmbh | $200.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $41.60 | 2025 | Opdivo |
| Gilead Sciences, INC. | $26.11 | 2025 | Trodelvy |
| Daiichi Sankyo INC. | $24.74 | 2025 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Glaxosmithkline, LLC. | $16.04 | 2025 | Ojjaara |
| Novartis Pharmaceuticals Corporation | $15.75 | 2025 | |
| Celgene Corporation | $13.45 | 2022 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atul Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.